Sarah A. Wall

Hematology
460 W 10th Ave Fl 5
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026

Outcomes of Tocilizumab for Cytokine Release Syndrome after Post-Transplant Cyclophosphamide.

Outcomes of Tocilizumab for Cytokine Release Syndrome after Post-Transplant Cyclophosphamide.

Journal: Transplantation and cellular therapy
Published: April 22, 2026

Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.

Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.

Journal: Blood advances
Published: October 24, 2025

Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.

Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.

Journal: Blood advances
Published: October 24, 2025

Successful engraftment in myeloablative transplant with cadaveric marrow after sudden unavailability of living donor.

Successful engraftment in myeloablative transplant with cadaveric marrow after sudden unavailability of living donor.

Journal: Blood advances
Published: October 24, 2025

CD34+-Selected Stem Cell Boost Provides Robust Outcomes in Patients With Poor Graft Function.

CD34+-Selected Stem Cell Boost Provides Robust Outcomes in Patients With Poor Graft Function.

Journal: Transplantation and cellular therapy
Published: September 24, 2025

CD34+-Selected Stem Cell Boost Provides Robust Outcomes in Patients With Poor Graft Function.

CD34+-Selected Stem Cell Boost Provides Robust Outcomes in Patients With Poor Graft Function.

Journal: Transplantation and cellular therapy
Published: September 24, 2025

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

Journal: Blood advances
Published: September 08, 2025

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances
Published: September 08, 2025

Combination ruxolitinib, belumosudil, and axatilimab yields clinically significant symptomatic improvements in treatment-refractory chronic GVHD.

Combination ruxolitinib, belumosudil, and axatilimab yields clinically significant symptomatic improvements in treatment-refractory chronic GVHD.

Journal: Bone marrow transplantation
Published: June 24, 2025

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study.

Journal: Blood neoplasia
Published: March 10, 2025

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.

Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.

Journal: Blood advances
Published: January 02, 2025
Showing 1-12 of 56

Last Updated: 09/26/2026